Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur

Virpax Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system (CNS) disorders, today announced that it will utilize leading pain expert, Dr. Neil K. Singla, to assist in the design and support of the clinical development strategy for Probudur.

Probudur is Virpax’s post-operative, ultra-long-acting anesthetic injection product candidate for post-operative pain management that is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications. Probudur’s proprietary formulation is intended for immediate onset and has demonstrated sustained pain control for up to 96 hours in animal studies. The Company entered into a cooperative research and development agreement (CRADA) in May of 2022 with the U.S. Army Institute of Surgical Research, the primary laboratory of the Department of Defense, to evaluate Probudur for trauma and critical care challenges.

Dr. Neil Singla is board certified in Anesthesiology and the Founder and Chief Scientific Officer of Lotus Clinical Research, a leading analgesic clinical research organization (CRO) with extensive analgesic and pain-related expertise. He has interacted frequently with the FDA’s Analgesics Division and is a nationally recognized key opinion leader in analgesic protocol design and implementation. Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country. He currently chairs the Analgesic Clinical Trials Shared/Special Interest Group at the International Association for the Study of Pain(IASP), chaired the Clinical Trials Shared Interest Group at the American Pain Society (APS) through 2019 and chairs the annual Conference on Analgesic Clinical Trials.

“We expect that Dr. Singla’s knowledge in the analgesic space, especially with liposomal bupivacaine, combined with his experience in regulatory affairs and study design will be of great value to us. I look forward to working with him and his team as we advance this product candidate,” commented Dr. Sheila A. Mathias, Chief Scientific Officer for Virpax.

“Virpax is actively moving its programs forward in anticipation of filing Investigational New Drug applications (INDs) and beginning human clinical trials. We are excited to have leading physicians and researchers who share our enthusiasm for our product candidates partnering with us,” concluded Anthony P. Mack, chairman and CEO of Virpax.